UK biotech startup Mogrify injects $16M to get novel cell therapies to market soon

TechCrunch | 10/14/2019 | Staff
Click For Photo: https://techcrunch.com/wp-content/uploads/2019/10/unnamed-2.jpg?w=600

Cambridge, UK-based biotech startup Mogrify, which is working on systematizing the development of novel cell therapies in areas such as regenerative medicine, has closed an initial $16 million Series A.

The raise follows a $4M seed in February — taking its total raised to date to $20M.

Mogrify - Approach - Analysis - Amounts - Data

Put simply, Mogrify’s approach entails analysis of vast amounts of genomic data in order to identify the specific energetic changes needed to flip an adult cell from one type to another without having to reset it to a stem cell state — with huge potential utility for a wide variety of therapeutic use-cases.

“What we’re trying to do with Mogrify is systematize that process where you can say here’s my source cell, here’s my target cell, here are the differences between the networks… and here are the most likely points of intervention that we’re going to have to make to drive the fate of an adult cell to another adult cell without going through a stem cell stage,” says CEO and investor Dr Darrin Disley.

Cells - Tries

So far he says it’s successfully converted 15 cells out of 15 tries.

“We’re now rapidly moving those on through our own programs and partnership programs,” he adds.

Mogrify - Business - Components - Program - Development

Mogrify’s business has three main components: Internal program development of cell therapies (current cell therapies it’s developing include enhancing augmented cartilage implantation; non-invasive treatment of ocular damage; and for blood disorders). It’s also developing a universal source of cells for use in immunotherapy — to act as “disease-eaters”, as Disley puts it.

Speculative IP development is another focus. “Because of the systematic nature of the technology we’re in a position very rapidly to identify areas of therapy that have particular cell conversions at their essence — and then drive that IP generation around those cells very quickly and create an IP footprint,” he says.

Deals

Partnering deals is the...
(Excerpt) Read more at: TechCrunch
Wake Up To Breaking News!
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!